Currently, the main focus for CombiGene is the epilepsy project, which aims at a safe and effective treatment for epilepsy patients. However, CombiGene’s platform holds opportunities for additional projects: Epilepsy is a common disorder in dogs, with a prevalence that is even higher than that for humans. Through the subsidiary CombiGene Vet AB, formed in 2015, a group of Danish scientists and veterinarians are currently sponsored in their efforts to study the effect of AAV vector-induced overexpression of NPY and Y2 in epileptic dogs. That study was subject to delays during 2016.
A decision was taken at the Annual Shareholders’ Meeting April 4th 2016 to distribute CombiGene Vet AB to CombiGene AB’s shareholders. More information regarding that is presented elsewhere.
Read more about epilepsy in dogs: Non-pharmacological treatment options utility in dogs …
In addition to epilepsy, CombiGene’s patent applications refer to other neurological diseases, as well as psychiatric diseases. Initially, CombiGene is now assessing the recent scientific advances and the medical needs in these fields, with the aim of selecting a preferred and feasible indication for further pre-studies and potential development project.
Read more about NPY’s role in CNS diseases: